Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
Observational · No treatment assigned · 1 site · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Primary Sclerosing Cholangitis. This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 18 to 90
- Any sex
- Healthy volunteers accepted
Some of the main requirements, copied from the record:
- PSC SUBJECTS:
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or nonpregnant female, greater than or equal to 18 years of age
- Evidence of PSC established by biochemical testing and either MRCP or ERCP. Participant must have evidence of large duct disease on imaging.
- Agreement to adhere to Lifestyle Considerations throughout study duration.
Plus 3 more requirement(s). There are also 35 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 143 participants are expected to take part.
- The study has 2 groups.
- Start date: 2023-03-31.
- Main results expected around 2026-10-31 (estimate from the record).
- 1 study site listed (1 marked recruiting) in United States.
Groups in this study
- Controls
- PSC Pariticipants
Main thing being measured
- The ultimate goal of this study is to generate understanding of how factors driving pathogenesis in PSC interact by capturing and integrating collated datasets from across relevant biologic systems… (End of Study)
In the researchers’ words
Background: Primary sclerosing cholangitis is a rare chronic liver disease. It affects the bile ducts of the liver. It can result in bile duct infections, cirrhosis, cancer, and end stage liver disease.
Words you might see
- MRCP: an MRI scan of the bile ducts and pancreas.
- ERCP: a procedure using a scope and dye to look at (and sometimes treat) the bile ducts.
- Cirrhosis: advanced scarring of the liver.
- Decompensated liver disease: advanced liver disease with complications such as fluid build-up or bleeding.
- Colonoscopy: a camera exam of the large intestine (colon).
- Endoscopy: a camera exam inside the digestive tract.
- Biologic: a medicine made from living cells, usually given by injection or infusion.
- Stricture: a narrowing (of the bowel or of a bile duct).
General definitions, not specific to this trial.
This summary was written automatically from the official record using fixed templates (no AI), so it only says what the record says, and may leave things out.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Primary Sclerosing Cholangitis |
| Lead sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Enrollment | 143 (estimated) |
| Start date | 2023-03-31 |
| Primary completion (est.) | 2026-10-31 |
| First posted | 2020-12-28 |
| Last updated | 2026-10-16 |
| Official title | Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach |
| ClinicalTrials.gov ID | NCT04685200 |
Interventions
- None listed
Full eligibility criteria (from the record)
* PSC SUBJECTS:
INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
1. Stated willingness to comply with all study procedures and availability for the duration of the study
2. Male or nonpregnant female, greater than or equal to 18 years of age
3. Evidence of PSC established by biochemical testing and either MRCP or ERCP. Participant must have evidence of large duct disease on imaging.
4. Agreement to adhere to Lifestyle Considerations throughout study duration.
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
1. Pregnant or lactating women or females of child-bearing age not taking measures to prevent pregnancy during the period of study.
2. History of clinical, serologic, or histopathologic evidence supporting etiologies of chronic liver disease other than PSC
3. History of liver transplantation
4. Diagnosis consistent with secondary sclerosing cholangitis (cholelithiasis, bile duct strictures secondary to ischemia, HIV cholangiopathy, etc.).
5. Current or past clinical evidence of decompensated liver disease (e.g. ascites, bleeding esophageal varices, spontaneous bacterial peritonitis, encephalopathy, etc.).
6. History of liver or bile duct lesions concerning for malignancy.
7. Ca-19-9 >130 U/microL
8. Alpha-fetoprotein level greater than 200 ng/microL.
9. Patients with active bacterial, viral, or fungal, systemic or localized infection.
10. Unwillingness to refrain from ingesting probiotics during study.
11. History of systemic disease not related to PSC that is poorly controlled or associated with declining functional status. Examples include but are not limited to: poorly controlled diabetes mellitus, chronic renal failure with eGFR is <60 microl/min/1.73m^2, chronic
symptomatic heart failure or severe COPD.
12. Patients with history of any gastrointestinal malignancy in the last 3 years prior to enrollment will be excluded. Patients with history of any malignancy in the last 3 years prior to enrollment other than those individuals who had undergone curative surgical therapy and deemed as low risk for recurrence by her/his treating physician would be excluded.
13. History of portal vein thrombosis
14. Patients with severe allergic reactions to iodine or other contrast, which cannot be controlled by premedication with antihistamines or steroids.
15. History of gastric and/or proximal small bowel surgery including bariatric surgery such as Roux-en-Y gastric bypass
16. Contraindication to monitored anesthesia care and/or medications that are commonly used for conscious sedation during GI Endoscopy
17. Use of anti-coagulant and anti-platelet agents excluding aspirin and NSAIDs
18. Contraindications to completing MRCP or MRI
19. Absolute neutrophil count below 1000/mm^3
20. Hemoglobin level below 10.0 g/dl
21. Platelet count lower than 50,000/mm^3.
22. INR greater than or equal to 1.5, PTT greater thna or equal to 1.3 times control and/or any known history of disease associated with
increased bleeding diathesis.
23. Inability to provide informed consent
CONTROLS:
INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
1. Male or female greater than or equal to 18 years of age
2. Any individual who is either a parent, sibling or child of a PSC patient enrolled to the study, or an unrelated person who has been living with the patient for at least 3 consecutive months before study enrollment
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
1. History suggestive of PSC
2. History of chronic liver disease (except for steatosis)
3. Patients with history of any malignancy in the 3 years prior to enrollment other than those individuals who had undergone curative surgical therapy and deemed as low risk for recurrence by her/his treating physician would be excluded.
4. History of Inflammatory Bowel Disease
5. Antibiotic use within the last 6 weeks
6. Pregnancy
7. Inability to provide informed consentLocations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| National Institutes of Health Clinical Center | Bethesda, Maryland | United States | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.